Royalty Pharma Expands Investor Engagement with Conferences

Royalty Pharma Engaging with Investors in December

Royalty Pharma plc (Nasdaq: RPRX) has exciting plans ahead as it gears up to actively engage with investors in December. The company has announced its participation in notable investor conferences designed to bolster its presence in the biopharmaceutical community.

Upcoming Conference Schedule

One of the highlights of this month will be the 7th Annual Evercore ISI HealthCONx Conference, where Royalty Pharma is set to present on Tuesday, December 3 at 12:55 p.m. ET. This prestigious conference brings together key players in the healthcare field, providing a platform for discussions on innovations and advancements in the industry.

Following that, Royalty Pharma will also be participating in Citi's 2024 Global Healthcare Conference on Wednesday, December 4 at 1:45 p.m. ET. This event will further enhance the company's visibility among investors and stakeholders alike.

Accessing Webcasts

For those interested in following these discussions closely, webcasts will be accessible on Royalty Pharma’s “Events” page. Additionally, these webcasts will be archived for at least thirty days, ensuring that stakeholders can revisit the valuable insights shared during the conferences.

About Royalty Pharma

Founded in 1996, Royalty Pharma has positioned itself as a leader in the biopharmaceutical industry by serving as the largest buyer of biopharmaceutical royalties. The company's innovative approach to funding fosters collaborations across a broad spectrum, from academic institutions and research hospitals to small and mid-cap biotechnology firms and major pharmaceutical players.

Portfolio of Innovation

Royalty Pharma has built an impressive portfolio that includes royalties linked to the top-line sales of many groundbreaking therapies. The firm actively invests in innovation within the biopharmaceutical sector by partnering with other companies to co-fund late-stage clinical trials and new product launches. Such collaborative efforts not only promote innovation but also yield substantial future royalties.

The company’s current portfolio features royalties on over 35 commercial products, including notable therapies such as Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, and Biogen’s Tysabri. This extensive roster further solidifies Royalty Pharma’s status as a critical player in the biopharmaceutical landscape.

Investor Relations Support

For those seeking more information or wishing to reach the investor relations team at Royalty Pharma, the direct contact is +1 (212) 883-6772. Investors can also reach out via email at ir@royaltypharma.com for inquiries regarding the company’s performance or investment opportunities.

Frequently Asked Questions

What conferences is Royalty Pharma attending in December?

Royalty Pharma will be attending the 7th Annual Evercore ISI HealthCONx Conference on December 3 and Citi’s 2024 Global Healthcare Conference on December 4.

How can I access the conference webcasts?

The webcasts can be accessed via Royalty Pharma’s “Events” page and will be archived for a minimum of thirty days.

What does Royalty Pharma do?

Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation across the industry by partnering with various organizations.

What notable products does Royalty Pharma’s portfolio include?

The portfolio includes royalties from products like Vertex's Trikafta, GSK's Trelegy, and Roche's Evrysdi, among others.

How can I contact Royalty Pharma’s investor relations?

You can reach Royalty Pharma’s investor relations at +1 (212) 883-6772 or by emailing ir@royaltypharma.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.